» Articles » PMID: 34117242

Analysis of the Genomic Landscape of Yolk Sac Tumors Reveals Mechanisms of Evolution and Chemoresistance

Overview
Journal Nat Commun
Specialty Biology
Date 2021 Jun 12
PMID 34117242
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Yolk sac tumors (YSTs) are a major histological subtype of malignant ovarian germ cell tumors with a relatively poor prognosis. The molecular basis of this disease has not been thoroughly characterized at the genomic level. Here we perform whole-exome and RNA sequencing on 41 clinical tumor samples from 30 YST patients, with distinct responses to cisplatin-based chemotherapy. We show that microsatellite instability status and mutational signatures are informative of chemoresistance. We identify somatic driver candidates, including significantly mutated genes KRAS and KIT and copy-number alteration drivers, including deleted ARID1A and PARK2, and amplified ZNF217, CDKN1B, and KRAS. YSTs have very infrequent TP53 mutations, whereas the tumors from patients with abnormal gonadal development contain both KRAS and TP53 mutations. We further reveal a role of OVOL2 overexpression in YST resistance to cisplatin. This study lays a critical foundation for understanding key molecular aberrations in YSTs and developing related therapeutic strategies.

Citing Articles

A matter of new life and cell death: programmed cell death in the mammalian ovary.

Chesnokov M, Mamedova A, Zhivotovsky B, Kopeina G J Biomed Sci. 2024; 31(1):31.

PMID: 38509545 PMC: 10956231. DOI: 10.1186/s12929-024-01017-6.


Subsequent ovarian yolk sac tumor after operation of ovarian mature teratoma: a case report and review of the literature.

Li S, Peng J, Zhang Y, Liu D, Li L, Nai M Front Oncol. 2024; 13:1327724.

PMID: 38298441 PMC: 10828046. DOI: 10.3389/fonc.2023.1327724.


Molecular Biology of Pediatric and Adult Ovarian Germ Cell Tumors: A Review.

Pinto M, Martins G, Santarosa Vieira A, Galvao J, Souza C, Pacheco Donato Macedo C Cancers (Basel). 2023; 15(11).

PMID: 37296950 PMC: 10251860. DOI: 10.3390/cancers15112990.

References
1.
Ellrott K, Bailey M, Saksena G, Covington K, Kandoth C, Stewart C . Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. Cell Syst. 2018; 6(3):271-281.e7. PMC: 6075717. DOI: 10.1016/j.cels.2018.03.002. View

2.
Miller C, White B, Dees N, Griffith M, Welch J, Griffith O . SciClone: inferring clonal architecture and tracking the spatial and temporal patterns of tumor evolution. PLoS Comput Biol. 2014; 10(8):e1003665. PMC: 4125065. DOI: 10.1371/journal.pcbi.1003665. View

3.
Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley D . Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat Protoc. 2012; 7(3):562-78. PMC: 3334321. DOI: 10.1038/nprot.2012.016. View

4.
Nasioudis D, Chapman-Davis E, Frey M, Caputo T, Holcomb K . Management and prognosis of ovarian yolk sac tumors; an analysis of the National Cancer Data Base. Gynecol Oncol. 2017; 147(2):296-301. DOI: 10.1016/j.ygyno.2017.08.013. View

5.
Wu R, Hong J, Wu J, Yan S, Wu D, Liu N . OVOL2 antagonizes TGF-β signaling to regulate epithelial to mesenchymal transition during mammary tumor metastasis. Oncotarget. 2017; 8(24):39401-39416. PMC: 5503621. DOI: 10.18632/oncotarget.17031. View